Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
A Phase II Pilot Study of the Safety, Tolerability and Pharmacokinetics of Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
Sponsor: Bellus Health Inc. - a GSK company
This PHASE2 trial investigates Neurologic Diseases, General and Stroke and is currently completed. Bellus Health Inc. - a GSK company leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bellus Health Inc. - a GSK company
- National Institute of Neurological Disorders and Stroke (NINDS)
For direct contact, visit the study record on ClinicalTrials.gov .